About Orphagen
Orphagen is a company based in San Diego (United States) founded in 2001. The company has 7 employees as of December 31, 2015. Orphagen offers products and services including OR-449, OR-812, and RORβ. Orphagen operates in a competitive market with competitors including Slingshot Bioscience, Magnitude Biosciences, StemoniX, InterAx Biotech and Signal Pharmaceuticals, among others.
- Headquarter San Diego, United States
- Employees 7 as on 31 Dec, 2015
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
- Legal Name Orphagen Pharmaceuticals
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
$1.7 M (USD), Grant
Dec 09, 2024
-
Investors
HHS
& 2 more
-
Employee Count
7
as on Dec 31, 2015
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Orphagen
Orphagen offers a comprehensive portfolio of products and services, including OR-449, OR-812, and RORβ.
Small molecule therapy for adrenal and squamous cancers
Targets nuclear receptors in cancer treatment
Small molecule for inflammatory diseases like ulcerative colitis
People of Orphagen
Unlock access to complete
Unlock access to complete
Leadership Team
3 people
Scientific Team
2 people
Board Team
1 people
Sales and Marketing
1 people
Unlock access to complete
Funding Insights of Orphagen
Investors in Orphagen
Orphagen has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS, National Institute of Diabetes and Digestive and Kidney Diseases and Vencore Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Research and health information on diabetes and kidney diseases are provided by NIDDK.
|
Locked | Locked | Locked | |
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked |
Investor details for Orphagen
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Orphagen
Investment portfolio details for Orphagen
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Orphagen
Detailed financials for Orphagen
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Orphagen Comparisons
Peer comparison for Orphagen
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Orphagen
Orphagen operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Slingshot Bioscience, Magnitude Biosciences, StemoniX, InterAx Biotech and Signal Pharmaceuticals, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Next-generation synthetic cells are developed for diagnostics and therapeutics.
|
|
| Locked | Locked | Locked |
Cell-free in vitro assays are supplied to drug discovery firms.
|
|
| Locked | Locked | Locked |
Developing a commercial scale printer for the high-volume growth and differentiation of stem cells and stem cell products.
|
|
| Locked | Locked | Locked |
Mutated arrestins are employed as biosensors for GPCR drug discovery.
|
|
| Locked | Locked | Locked |
Small molecule drugs regulating disease-associated genes are developed.
|
|
| Locked | Locked | Locked |
Sequence Bio is a Newfoundland and Labrador biotechnology company striving to improve how we treat diseases and develop medicines.
|
Detailed competitors of Orphagen
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Orphagen
Complete news archive for Orphagen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Orphagen
Orphagen was founded in 2001 and raised its 1st funding round 4 years after it was founded.
Orphagen is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
As of Dec 31, 2015, the latest employee count at Orphagen is 7.
Founded in 2001, Orphagen operates as a preclinical-stage drug discovery and research services firm in San Diego, United States. Focus is placed on translational research targeting orphan nuclear receptors for conditions such as autoimmune diseases, Cushings syndrome, and retinal degeneration. Validated transcriptional and biochemical assays are provided on a contract basis for steroid hormone, metabolic, retinoid, and orphan receptors, with custom assay development available upon request.
Orphagen's top competitors include Magnitude Biosciences, Slingshot Bioscience and StemoniX.
Orphagen offers OR-449, OR-812, and RORβ.
Orphagen has 3 investors. Key investors include HHS, National Institute of Diabetes and Digestive and Kidney Diseases, and Vencore Capital.